Riding high on new interim data suggesting plasma-derived alpha-1 antitrypsin (AAT) might help patients with graft-vs.-host disease (GvHD) recover when steroids fail, Omni Bio Pharmaceutical Inc. is angling to produce an irresistible proof-of-concept package showing its preclinical recombinant AAT (rAAT) could do the same and more.
